Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 11/20 | 0.43 |
| ▸ | TSHR | P16473 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5598644 | 0.78 | NAMPT (0.35) | — | |
| SCHEMBL432878 | 0.74 | CYP3A4 (0.52) | NPSR1LMNAMEN1USP2KMT2A | |
| SCHEMBL27428610 | 0.68 | NPSR1 (0.59) | NPSR1LMNAMEN1USP2KMT2A | |
| SCHEMBL4381915 | 0.67 | PDE5A (0.69) | PDE5ATBXAS1PDE3BPDE3APTGS1 | |
| SCHEMBL19764716 | 0.66 | LMNA (0.93) | NPSR1LMNAMEN1USP2KMT2A | |
| SCHEMBL20957843 | 0.65 | NPSR1 (0.54) | NPSR1LMNAMEN1USP2KMT2A | |
| SCHEMBL8302217 | 0.63 | PDE5A (0.59) | NPSR1LMNAMEN1USP2KMT2A | |
| SCHEMBL8544658 | 0.62 | PDE5A (0.41) | NPSR1LMNAMEN1USP2KMT2A | |
| SCHEMBL15289603 | 0.61 | LMNA (0.60) | NPSR1LMNAMEN1USP2KMT2A | |
| SCHEMBL715585 | 0.61 | PDE5A (1.00) | PDE5ATBXAS1PDE3BPDE3APTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090041675-A1 | Organic compounds | TRIFILIEFF ALEXANDRE | 2009-02-12 | — | — | US | claimed |
| EP-1140044-B1 | cGMP PDE 5 INHIBITORS FOR INHALATION IN THE TREATMENT OF SEXUAL DYSFUNCTION | NOVARTIS AG (CH) | 2006-03-15 | — | — | EP | claimed |
| US-10994082-B2 | Inhaler counter | ASTRAZENECA AB (SE) | 2021-05-04 | — | — | US | disclosed |
| US-20190175849-A1 | INHALER COUNTER | BANG & OLUFSEN MEDICOM A/S (DK) | 2019-06-13 | — | — | US | disclosed |
| US-20180339119-A1 | INHALER | BANG & OLUFSEN MEDICOM A/S (DK) | 2018-11-29 | — | — | US | disclosed |
| EP-2755707-B1 | INHALER | ASTRAZENECA AB (SE) | 2018-11-14 | — | — | EP | disclosed |
| EP-3345644-A1 | INHALER | Astrazeneca AB (SE) | 2018-07-11 | — | — | EP | disclosed |
| EP-2755708-B1 | INHALER | ASTRAZENECA AB (SE) | 2018-05-09 | — | — | EP | disclosed |
| EP-2448623-B1 | DISPENSER AND METHOD FOR ENTRAINING POWDER IN AN AIRFLOW | ASTRAZENECA AB (SE) | 2017-12-20 | — | — | EP | disclosed |
| EP-2341968-B1 | A BREATH ACTIVATED INHALER | ASTRAZENECA AB (SE) | 2017-05-10 | — | — | EP | disclosed |
| US-9289565-B2 | Inhaler with indexing linked to movement of cover | ASTRAZENECA AB (SE) | 2016-03-22 | — | — | US | disclosed |
| CN-101652137-A | Combinations of beta- 2 -adrenoceptor agonistic benzothiazolone | ASTRAZENECA AB SE | 2010-02-17 | — | — | CN | disclosed |
| US-20100029732-A1 | Combinations of Beta-2-Adrenoceptor Agonistic Benzothiazolone | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| EP-2117542-A1 | COMBINATIONS OF BETA- 2 -ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | AstraZeneca AB (SE) | 2009-11-18 | — | — | EP | disclosed |
| WO-2009037503-A2 | NEW COMBINATION - 012 FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2009-03-26 | — | — | WO | disclosed |
| US-20090041675-A1 | Organic compounds | TRIFILIEFF ALEXANDRE | 2009-02-12 | — | — | US | disclosed |
| US-20080242649-A1 | New Combination 665 | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | US | disclosed |
| WO-2008104776-A1 | COMBINATIONS OF BETA-2-ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008096111-A1 | COMBINATIONS OF BETA- 2 -ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096121-A1 | COMBINATIONS OF BETA-2-ADRENOCEPTOR AGONISTIC BENZOTHIAZOLONE | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041675-A1 | Organic compounds | PDE12, PDE5A, RXFP4 | NPSR1 473/4885LMNA 4127/4885MEN1 4412/4885 |
| US-20080242649-A1 | New Combination 665 | NR3C2, PTGER2, GRK5 | NPSR1 1658/4885LMNA 3129/4885MEN1 4750/4885 |
| US-20100029732-A1 | Combinations of Beta-2-Adrenoceptor Agonistic Benzothiazolone | NR3C2, NR3C1, ARRB1 | NPSR1 1128/4885LMNA 3077/4885MEN1 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.